<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04097093</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC 1826-STBSG</org_study_id>
    <nct_id>NCT04097093</nct_id>
  </id_info>
  <brief_title>Long-term Surival of GIST Patients ≥ 10 Years on Imatinib</brief_title>
  <official_title>Long-term Survival of Advanced/Metastatic GIST Patients Responding to Imatinib Treatment: an Observational Follow-up Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a cross-sectional cohort study of metastatic GastroIntestinal Stromal Tumor (GIST)
      patients on imatinib for ≥ 10 years included in EORTC trial 62005-STBSG entitled &quot;Phase 3
      randomized, intergroup, international tiral assessing the clinical activity of STI-571 at two
      dose levels in patients with unresectable or metastatic gastrointestinal stromal tumor (GIST)
      expressing the KIT receptor tyrosine kinase (CD117) - NCT00685828&quot;. With this study, the aim
      is to identify patient characteristics, tumour characteristics, treatment factors and quality
      of life outcomes associated with prolonged treatment with imatinib and/or prolonged survival.
      This observational study will further help to put in place a questionnaire to evaluate
      patients quality of life with prolonged imatinib treatment, that will then be used in a
      prospective study.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Patient characteristics</measure>
    <time_frame>At time of registration</time_frame>
    <description>Age at time of randomization, gender, medical history and previous treatment(s)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumour characteristics</measure>
    <time_frame>At time of registration</time_frame>
    <description>Stage of the disease, tumor grade, tumor location and molecular features of primary tumor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of imatinib treatment</measure>
    <time_frame>At time of registration</time_frame>
    <description>Time on imatinib treatment from start untill definitive discontinuation of imatinib treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health releated quality of life</measure>
    <time_frame>At time of registration</time_frame>
    <description>QLQ-C30</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>At time of registration</time_frame>
    <description>From time of randomization to the date of death, whatever the cause</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">65</enrollment>
  <condition>GIST</condition>
  <arm_group>
    <arm_group_label>Study 62005-STBSG patients treated with imatinib &gt; 10 years</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>Study 62005-STBSG patients treated with imatinib &gt; 10 years</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      First, existing data on molecular characteristics of included patients will be collected from
      the treating centers. If more than 40% of the data is not available, archival tumor tissue
      from patients enrolled in the EORTC 62005-STBSG study will be collected and used to identify
      molecular characteristics of the tumor that may predict long-term response to imatinib.
      Archival tumor tissues will be retrieved from the central lab of the study 62005-STBSG (UZ
      Leuven, Belgium) or from the sites (if applicable).
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients enrolled in the 62005 trial - treated for more than 10 years with imatinib - will
        be enrolled in this study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients included in the EORTC 62005 trial: Adult patients with metastasized GIST

          -  Patients who have been treated with imatinib for ten years or longer

          -  For the identified patients who are still alive:

               1. Able to read and answer questionnaires

               2. Able to provide written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>28 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neeltje Steeghs</last_name>
    <role>Study Chair</role>
    <affiliation>NKI - Antoni van Leeuwenhoekziekenhuis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Axel Le Cesne</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ingrid Desar</last_name>
    <role>Study Chair</role>
    <affiliation>Radboud University Medical Center Nijmegen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olga Husson</last_name>
    <role>Study Chair</role>
    <affiliation>Radboud University Medical Center Nijmegen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>EORTC HQ</last_name>
    <phone>+32 2 774 1611</phone>
    <email>1826@eortc.org</email>
  </overall_contact>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 7, 2019</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>December 24, 2019</last_update_submitted>
  <last_update_submitted_qc>December 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

